scholarly journals Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival

Cancer ◽  
2009 ◽  
Vol 115 (3) ◽  
pp. 581-586 ◽  
Author(s):  
Katherine R. Birchard ◽  
Jenny K. Hoang ◽  
James E. Herndon ◽  
Edward F. Patz
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Nonsmall Cell Lung Cancer ◽  
Advanced Stage

scholarly journals A prognostic model for advanced stage nonsmall cell lung cancer

Cancer ◽  
2006 ◽  
Vol 107 (4) ◽  
pp. 781-792 ◽  
Author(s):  
Sumithra J. Mandrekar ◽  
Steven E. Schild ◽  
Shauna L. Hillman ◽  
Katie L. Allen ◽  
Randolph S. Marks ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Model ◽  
Nonsmall Cell Lung Cancer ◽  
Advanced Stage

Survival After Pathological Stage IA Nonsmall Cell Lung Cancer: Tumor Size Matters

2005 ◽  
Vol 79 (4) ◽  
pp. 1137-1141 ◽  
Author(s):  
Özcan Birim ◽  
A. Pieter Kappetein ◽  
Johanna J.M. Takkenberg ◽  
Rob J. van Klaveren ◽  
Ad J.J.C. Bogers
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Nonsmall Cell Lung Cancer ◽  
Pathological Stage ◽  
Cancer Tumor ◽  
Stage Ia

scholarly journals Biological therapies in nonsmall cell lung cancer

2017 ◽  
Vol 49 (3) ◽  
pp. 1601520 ◽  
Author(s):  
Jon Zugazagoitia ◽  
Sonia Molina-Pinelo ◽  
Fernando Lopez-Rios ◽  
Luis Paz-Ares
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Nonsmall Cell Lung Cancer ◽  
Advanced Stage ◽  
Biological Therapies ◽  
Term Survival ◽  
Treatment Benefits ◽  
Medical Disciplines

Biological therapies have improved survival outcomes of advanced-stage nonsmall cell lung cancer (NSCLC). Genotype-directed therapies have changed treatment paradigms of patients withEGFR-mutant andALK/ROS1-rearranged lung adenocarcinomas, and the list of druggable targets with demonstrated clinical actionability (BRAF, MET, RET, NTRK1andHER2) continues to expand. Furthermore, we have incrementally understood the mechanisms of cancer immune evasion and foresee ways to effectively circumvent them, particularly at the immune checkpoint level. Drugs targeting the tumour immune-evasive PD-1 pathway have demonstrated remarkable treatment benefits in this disease, with a non-negligible fraction of patients potentially receiving long-term survival benefits. Herein, we briefly discuss the role of various medical disciplines in the management of advanced-stage NSCLC and review the most relevant biological therapies for this disease, with particular emphasis in genotype-directed therapies and immune checkpoint inhibitors.

scholarly journals Correlation of quantified metabolic activity in nonsmall cell lung cancer with tumor size and tumor pathological characteristics

Medicine ◽  
2018 ◽  
Vol 97 (32) ◽  
pp. e11628 ◽  
Author(s):  
Mehrdad Bakhshayesh Karam ◽  
Abtin Doroudinia ◽  
Bahareh Behzadi ◽  
Payam Mehrian ◽  
Abbas Yousefi Koma
Keyword(s):  
Lung Cancer ◽  
Metabolic Activity ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Nonsmall Cell Lung Cancer ◽  
Pathological Characteristics

scholarly journals Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules

Cancer ◽  
2007 ◽  
Vol 112 (1) ◽  
pp. 136-143 ◽  
Author(s):  
Jason A. Zell ◽  
S.-H. Ignatius Ou ◽  
Argyrios Ziogas ◽  
Hoda Anton-Culver
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Advanced Stage
Sign in / Sign up

Export Citation Format

Share Document